• Careers
  • Trial Participants
  • Investors
  • Submit an RFP
  • Choose Language
  • Search
  • Scientific Expertise
    Scientific Expertise >
    Therapeutic Areas
    Therapeutic Areas >
    Cardiovascular Dermatology Diabetes and Endocrinology Hepatology Infectious Disease Inflammation Nephrology Neuroscience Oncology Ophthalmology Respiratory & Pulmonary Rheumatoid Arthritis
    Specialty Areas
    Specialty Areas >
    Cell and Gene Therapies Pediatrics Rare Diseases
  • Global Solutions
    Global Solutions >
    Clinical Development
    Clinical Development >
    Early: Phase I / IIa Late: Phase IIb / III Real-World Evidence and Post-Approval Studies Decentralized Clinical Trials Data Analysis & Reporting Clinical Trial Project Management & Monitoring Patient Safety & Pharmacovigilance
    Clinical Pharmacology
    Clinical Pharmacology >
    Clinical Research Units (CRUs)
    Drug Development Consulting
    Drug Development Consulting >
    Market Access & HEOR Strategy Regulatory Strategy Consulting Product Development Team
    Enabling Technologies
    Enabling Technologies >
    Mobile Clinical Services
    Full and Functional Service Provider Models
    Full and Functional Service Provider Models >
    Hub and Patient Access Support
    Hub and Patient Access Support >
    Specialty Pharmacy
    Device and Diagnostic Development
    Device and Diagnostic Development >
  • Our Customers
    Our Customers >
    Pharmaceutical
    Pharmaceutical >
    Biotechnology
    Biotechnology >
    Med Tech
    Med Tech >
  • About Us
    About Us >
    Blog
    Blog >
    Promoting access to innovative cardiac medical devices through diversity and inclusion SGLT2 inhibitors as renoprotective agents for pediatric patients living with chronic kidney disease Five ways Fortrea's new Shanghai office is promoting sustainability and environmental stewardship
    Locations
    Locations >
    Investors
    Investors >
    Leadership
    Leadership >
    Newsroom
    Newsroom >
Contact Us
Back
alt text alt text

Blog: Fresh insights driving agile collaboration

Home /  About Us /  Blog
  • Five ways Fortrea's new Shanghai office is promoting sustainability and environmental stewardship Read more about Five ways Fortrea's new Shanghai office is promoting sustainability and environmental stewardship
  • SGLT2 inhibitors as renoprotective agents for pediatric patients living with chronic kidney disease Read more about SGLT2 inhibitors as renoprotective agents for pediatric patients living with chronic kidney disease
  • Promoting access to innovative cardiac medical devices through diversity and inclusion Read more about Promoting access to innovative cardiac medical devices through diversity and inclusion
  • Key takeaways from the 2023 SCDM AC & Leadership Forum Read more about Key takeaways from the 2023 SCDM AC & Leadership Forum
  • Standardizing cosmetovigilence Read more about Standardizing cosmetovigilence
  • Advancing cell and gene therapy frontiers Read more about Advancing cell and gene therapy frontiers
  • Patient safety in clinical trials Read more about Patient safety in clinical trials
  • Leveraging precision medicine to advance clinical trials in Latin America Read more about Leveraging precision medicine to advance clinical trials in Latin America
  • Fix, replace or augment: Key considerations for rescue or transition studies in medical device clinical trials Read more about Fix, replace or augment: Key considerations for rescue or transition studies in medical device clinical trials
Fotrea Logo
Quick Links
  • Scientific Expertise
  • Global Solutions
  • Our Customers
  • About Us
  • Blog
Resources
  • Careers
  • Trial Participants
  • Investigator Login
  • Contact Us
Legal
  • Legal and Compliance
  • Terms and Conditions
  • Privacy Policy
  • California & Virginia Privacy Policy
  • Combatting Modern Slavery & Human Trafficking Statement
  • Non-Discrimination Policy
Follow Us
  • LinkedIn
  • Twitter
  • Facebook
  • LinkedIn
  • Twitter
  • Facebook
Labcorp Clinical Development and Commercialization Services business is now Fortrea (NASDAQ: FTRE). Ⓒ 2023 Copyright Fortrea Inc. All Rights Reserved.